Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.44 Million EUR | 79.36% |
| 2022 | -40.93 Million EUR | -54.4% |
| 2021 | -26.51 Million EUR | -51.49% |
| 2020 | -17.5 Million EUR | 38.88% |
| 2019 | -28.63 Million EUR | 21.15% |
| 2018 | -36.31 Million EUR | 35.61% |
| 2017 | -56.39 Million EUR | -138.9% |
| 2016 | -23.6 Million EUR | 18.92% |
| 2015 | -29.11 Million EUR | -76.95% |
| 2014 | -16.45 Million EUR | -33.26% |
| 2013 | -12.34 Million EUR | -473.56% |
| 2012 | -2.15 Million EUR | 76.43% |
| 2011 | -9.13 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.04 Million EUR | 0.0% |
| 2023 FY | -8.44 Million EUR | 79.36% |
| 2023 Q4 | -4.7 Million EUR | 0.0% |
| 2023 Q2 | -3.74 Million EUR | 0.0% |
| 2022 FY | -40.93 Million EUR | -54.4% |
| 2022 Q4 | -26.87 Million EUR | 0.0% |
| 2022 Q2 | -6.37 Million EUR | 15.4% |
| 2022 Q1 | -7.53 Million EUR | -76.4% |
| 2021 Q2 | -6.12 Million EUR | 29.59% |
| 2021 Q4 | -4.27 Million EUR | 41.26% |
| 2021 FY | -26.51 Million EUR | -51.49% |
| 2021 Q1 | -8.7 Million EUR | -280.37% |
| 2021 Q3 | -7.27 Million EUR | -18.69% |
| 2020 FY | -17.5 Million EUR | 38.88% |
| 2020 Q3 | -5.43 Million EUR | 67.28% |
| 2020 Q4 | 4.82 Million EUR | 188.82% |
| 2020 Q2 | -16.59 Million EUR | 0.0% |
| 2019 Q2 | -15.96 Million EUR | -123.04% |
| 2019 FY | -28.63 Million EUR | 21.15% |
| 2019 Q4 | -12.66 Million EUR | 0.0% |
| 2019 Q1 | -7.15 Million EUR | 62.26% |
| 2018 Q2 | -18.45 Million EUR | -96.95% |
| 2018 Q1 | -9.37 Million EUR | 77.67% |
| 2018 FY | -36.31 Million EUR | 35.61% |
| 2018 Q4 | -18.96 Million EUR | 0.0% |
| 2017 Q2 | -14.41 Million EUR | -2.24% |
| 2017 FY | -56.39 Million EUR | -138.9% |
| 2017 Q4 | -41.98 Million EUR | 0.0% |
| 2017 Q1 | -14.09 Million EUR | -111.06% |
| 2016 Q4 | -6.68 Million EUR | 0.0% |
| 2016 FY | -23.6 Million EUR | 18.92% |
| 2016 Q2 | -16.92 Million EUR | -186.81% |
| 2016 Q1 | -5.9 Million EUR | 57.16% |
| 2015 Q4 | -13.77 Million EUR | -88.61% |
| 2015 FY | -29.11 Million EUR | -76.95% |
| 2015 Q3 | -7.3 Million EUR | 52.39% |
| 2015 Q2 | -15.33 Million EUR | -110.02% |
| 2015 Q1 | -7.3 Million EUR | 27.49% |
| 2014 Q1 | -4.11 Million EUR | 48.91% |
| 2014 FY | -16.45 Million EUR | -33.26% |
| 2014 Q4 | -10.07 Million EUR | -144.54% |
| 2014 Q3 | -4.11 Million EUR | 35.45% |
| 2014 Q2 | -6.38 Million EUR | -54.93% |
| 2013 Q3 | -3.19 Million EUR | 50.33% |
| 2013 Q4 | -8.06 Million EUR | -152.47% |
| 2013 FY | -12.34 Million EUR | -473.56% |
| 2013 Q1 | -3.19 Million EUR | 0.0% |
| 2013 Q2 | -6.42 Million EUR | -101.31% |
| 2012 Q2 | -538.13 Thousand EUR | 0.0% |
| 2012 FY | -2.15 Million EUR | 76.43% |
| 2012 Q1 | -538.13 Thousand EUR | 0.0% |
| 2012 Q3 | -538.13 Thousand EUR | 0.0% |
| 2012 Q4 | -3.19 Million EUR | -493.33% |
| 2011 Q4 | -538.13 Thousand EUR | 76.43% |
| 2011 Q1 | -2.28 Million EUR | 0.0% |
| 2011 Q2 | -2.28 Million EUR | 0.0% |
| 2011 Q3 | -2.28 Million EUR | 0.0% |
| 2011 FY | -9.13 Million EUR | 0.0% |
| 2010 Q4 | -2.28 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -140.136% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 94.282% |
| Adocia SA | -21.16 Million EUR | 60.079% |
| Aelis Farma SA | -5.07 Million EUR | -66.365% |
| Biophytis S.A. | -17.02 Million EUR | 50.382% |
| Advicenne S.A. | -7.03 Million EUR | -20.154% |
| genOway Société anonyme | 1.56 Million EUR | 638.922% |
| IntegraGen SA | -171.39 Thousand EUR | -4828.85% |
| Medesis Pharma S.A. | -3.95 Million EUR | -113.361% |
| Neovacs S.A. | -8.74 Million EUR | 3.379% |
| NFL Biosciences SA | -3.74 Million EUR | -125.552% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 10770.843% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -166.419% |
| Sensorion SA | -22.06 Million EUR | 61.71% |
| Theranexus Société Anonyme | -6.82 Million EUR | -23.727% |
| TME Pharma N.V. | -6.73 Million EUR | -25.416% |
| Valbiotis SA | -7.36 Million EUR | -14.658% |
| TheraVet SA | -1.57 Million EUR | -437.847% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 58.474% |
| argenx SE | -272.91 Million EUR | 96.905% |
| BioSenic S.A. | -28.77 Million EUR | 70.644% |
| DBV Technologies S.A. | -67.26 Million EUR | 87.442% |
| Galapagos NV | 211.69 Million EUR | 103.991% |
| Genfit S.A. | -28.89 Million EUR | 70.762% |
| GeNeuro SA | -14.75 Million EUR | 42.753% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 45.072% |
| Innate Pharma S.A. | -7.57 Million EUR | -11.598% |
| Inventiva S.A. | -110.42 Million EUR | 92.35% |
| MaaT Pharma SA | -19.71 Million EUR | 57.154% |
| MedinCell S.A. | -25.03 Million EUR | 66.259% |
| Nanobiotix S.A. | -39.7 Million EUR | 78.72% |
| Onward Medical N.V. | -36.18 Million EUR | 76.651% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -151.958% |
| OSE Immunotherapeutics SA | -23 Million EUR | 63.274% |
| Oxurion NV | -18.96 Million EUR | 55.464% |
| Pharming Group N.V. | -9.75 Million EUR | 13.412% |
| Poxel S.A. | -35.09 Million EUR | 75.925% |
| GenSight Biologics S.A. | -26.22 Million EUR | 67.78% |
| Transgene SA | -22.32 Million EUR | 62.164% |
| Financière de Tubize SA | 88.15 Million EUR | 109.584% |
| UCB SA | 343 Million EUR | 102.463% |
| Valneva SE | -101.42 Million EUR | 91.671% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 70.193% |